FAQ: What mFLUSIVA's Approval May Signal for the Future of mRNA Vaccine Development

Moderna's mFLUSIVA approval on August 5, 2026, marks a milestone for mRNA vaccine development, offering insight into regulatory considerations that may influence future mRNA vaccine submissions, including comparator selection, accelerated approval strategies, and clinical development planning.

With the first US licensure of an mRNA-based seasonal influenza vaccine, comes an opportunity to examine how FDA is evaluating emerging mRNA vaccine programs, how expedited pathways are being applied to newer vaccine platforms, and what lessons sponsors developing similar products may take from the review process.

Does this approval indicate a broader shift in FDA's evaluation of mRNA vaccine submissions?

The regulatory path for mFLUSIVA highlights several considerations that may be relevant for future mRNA vaccine developers, but the approval does not necessarily indicate a broader change in FDA's approach to the platform.

Earlier in the review process, Moderna received a refusal-to-file letter related to the comparator used in data submitted from its older-adult pivotal trial. The issue centered on the use of a standard-dose licensed comparator rather than a high-dose influenza vaccine comparator in that population. Moderna had also exercised a Priority Review Voucher to facilitate review of the application.¹ Following additional discussions with FDA, the application ultimately received traditional approval for adults ages 50 to 64 and accelerated approval for those 65 and older.¹

For sponsors developing vaccines intended for older adults, the review highlights the importance of comparator selection and early alignment with regulatory expectations. Rather than signaling a different standard for mRNA vaccines, the approval provides another example of FDA applying established vaccine review principles to an emerging platform.

How does mFLUSIVA's approval affect competing mRNA influenza vaccine programs?

mFLUSIVA's approval establishes a regulatory precedent for mRNA-based influenza vaccines in the US and gives competing developers additional insight into the considerations involved in bringing similar products forward.

Pfizer and BioNTech previously reported phase 3 results for their modRNA influenza vaccine candidate, which met noninferiority and superiority endpoints versus a licensed influenza vaccine in adults ages 18 to 64 in the primary analysis, although secondary immunogenicity endpoints were achieved for influenza A but not B.²² Sanofi is also developing an mRNA influenza vaccine program.³

While mFLUSIVA's approval provides Moderna with first-mover status in the US market, it does not eliminate opportunities for other developers. Future differentiation may depend on factors including clinical performance, dosing strategies, manufacturing approaches, and the ability to demonstrate meaningful advantages for specific populations.

For sponsors with competing programs, the approval may offer additional visibility into FDA's expectations around clinical trial design, comparator selection, and regulatory review considerations.

What does the accelerated approval pathway mean for mFLUSIVA's long-term regulatory status?

The approval includes different regulatory pathways for different age groups. Adults ages 50 to 64 received traditional approval based on clinical efficacy data, while the indication for adults 65 and older was granted under the accelerated approval pathway based on an immune response endpoint that FDA considers reasonably likely to predict clinical benefit.⁴

For mFLUSIVA, Moderna is required to conduct a postmarketing study to verify clinical benefit in adults 65 and older. If confirmatory studies fail to demonstrate benefit, or if required studies are not completed with due diligence, FDA has authority to take regulatory action, including withdrawal of the indication covered by accelerated approval.⁴

For developers, the decision illustrates how accelerated approval can provide earlier access for important therapies while maintaining requirements for additional evidence generation after approval.

What does mFLUSIVA's approval mean for mRNA development beyond COVID-19 vaccines?

One important implication of mFLUSIVA's approval is what it may mean for broader mRNA platform development.

The approval represents the first US-licensed mRNA vaccine for a non-COVID-19 indication, demonstrating that the platform can progress through the standard vaccine regulatory pathway beyond the emergency use authorizations that supported the initial deployment of COVID-19 mRNA vaccines.

For companies developing mRNA-based vaccines and therapeutics, the decision provides another regulatory case study for navigating clinical development, manufacturing considerations, and submission strategies for the platform.

The approval may also influence expectations around other mRNA programs in development, including Moderna's individualized neoantigen cancer vaccine program, intismeran autogene (mRNA-4157/V940), which is being evaluated in combination with Merck's pembrolizumab in the fully enrolled Phase 3 INTerpath-001 trial in adjuvant melanoma.⁵ In a company press release, Kyle Holen, MD, Moderna's senior vice president and head of development, oncology and therapeutics, said, “We continue to invest in our platform in oncology because of encouraging outcomes like these, which illustrate mRNA's potential in cancer care. We look forward to several additional milestones to come, including the results of our Phase 3 study in adjuvant melanoma in collaboration with Merck, and continued progress across the eight Phase 2 and Phase 3 studies in multiple tumor types and patient populations.”⁵

What are the broader implications for future mRNA vaccine development?

mFLUSIVA's approval does not establish that all mRNA products will follow the same regulatory path, but it does provide additional insight into how FDA may evaluate future submissions involving the technology.

For sponsors developing next-generation vaccines and other mRNA-based medicines, key considerations will likely include selecting appropriate comparators, designing trials that generate meaningful clinical evidence, engaging regulators early, and planning manufacturing strategies that can support eventual commercialization.

As more complex biologics and advanced therapies enter development, regulatory pathways will continue to evolve alongside the science. For companies working in emerging modalities, understanding how FDA evaluates each individual product, rather than relying on platform assumptions, will remain critical.

References

1. Moderna, Inc. Notification of FDA refusal-to-file letter for mRNA-1010 biologics license application. Form 8-K exhibit. US Securities and Exchange Commission; February 10, 2026. Accessed August 7, 2026.
2. Pfizer Inc. First-generation modRNA influenza vaccine candidate (PF-07252220) meets primary endpoints in Phase III trial. Form 8-K exhibit. US Securities and Exchange Commission; 2023. Accessed August 7, 2026.
3. Taaffe J, Ostrowsky JT, Mott J. et al. Advancing influenza vaccines: a review of next-generation candidates and their potential for global health impact. Vaccine. 2024. doi: 10.1016/j.vaccine.2024.126408
4. US Food and Drug Administration. 21 CFR 601.41: Approval based on a surrogate endpoint or on an effect on a clinical endpoint other than survival or irreversible morbidity. Electronic Code of Federal Regulations. Accessed August 7, 2026.
5. Moderna, Inc.; Merck & Co. Moderna & Merck announce 5-year data for intismeran autogene in combination with KEYTRUDA (pembrolizumab) demonstrated sustained improvement in the primary endpoint of recurrence-free survival in patients with high-risk stage III/IV melanoma following complete resection. News release. Merck & Co; January 20, 2026. Accessed August 7, 2026.